DCCT/EDIC Study Published Results: 2000-2009

  • Nathan DM, Zinman B, Cleary PA, Backlund JYC, Genuth S, Miller R, Orchard TJ, and the DCCT/EDIC Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years duration.  Arch Intern Med 2009, 169(14):1307-1316. PMCID:2866072.
  • Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin, JM, Herman WH, and the DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus.  Circulation 2009, 119(22):2886-2893. PMCID:2757005.
  • Pezzolesi MG, Poznik D, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DPK, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, DCCT/EDIC Research Group, Doria A, Rogus JJ, Rich SS, Warram JH, and Krolewski AS.  Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes.  Diabetes 2009, 58(6):1403-1410. PMCID:2682673.
  • Penson DF, Wessells H, Cleary P, Rutledge BN, and the DCCT/EDIC Research Group.  Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. J Sex Med 2009, 6(7):1969-1978. PMCID:2861494.
  • Sarma AV, Kanaya A, Nyberg LM, Kusek JW, Vittinghoff E, Rutledge B, Cleary PA, Gatcomb P, Brown JS, and the DCCT/EDIC Research Group. Risk factors for urinary incontinence among women with type 1 diabetes: Findings from the Epidemiology of Diabetes Interventions and Complications study. Urology 2009, 73(6):1203-1209. PMCID:2748226.
  • Enzlin P, Rosen R, Wiegel M, Brown J, Wessells, Gatcomb P, Rutledge B, Chan KL, Cleary PA, and the DCCT/EDIC Research Group.  Sexual dysfunction in women with type 1 diabetes: Long-term findings from the DCCT/EDIC study cohort.  Diabetes Care 2009, 32(5):780-785. PMCID:2671088.
  • Van Den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, McVary KT, Wessells H, and the DCCT/EDIC Research Group. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms (LUTS) in men with type 1 diabetes.  Diabetes Care 2009, 32(4):664-670. PMCID:2660483.
  • Sarma AV, Kanaya AM, Nyberg LM, Kusek JW, Vittinghoff E, Rutledge B, Cleary PA, Gatcomb P, and Brown JS, and the DCCT/EDIC Research Group.  Urinary incontinence among women with type 1 diabetes – How common is it? J Urol 2009, 181(3):1224-1230. PMICID:2696131.
  • Czaja CA, Rutledge BN, Cleary PA, Chan K, Stapleton AE, Stamm WE, f and the DCCT/EDIC Research Group. Urinary tract infections in women with type 1 diabetes mellitus: Survey of female participants in the Epidemiology of Diabetes Interventions and Complications study cohort.  J Urol, 2009 181(3):1129-1135. PMCID:2699609.
  • Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler DJ, and the DCCT/EDIC Research Group. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 2009, 89(2):518-524. PMCID:2647518.
  • Deeb SS, Brunzell JD. The Role of the PGC1 & Gly482Ser Polymorphism in weight gain due to intensive diabetes therapy. PPAR Res 2009, 2009:649286 EPub April. PMCID:2666270.
  • Grant SFA, Qu HQ, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Skraban R, Imielinski M, Chiavacci RM, Grundmeier RW, Stanley CA, Kirsch SE, Waggott D, Paterson AD, Monos DS, and the DCCT/EDIC Research Group. Polychronakos C, Hakonarson H.  Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes.  Diabetes 2009, 58(1):290-295. PMCID:2606889.
  • Nolte IM, Wallace C, Newhouse SJ, Waggott D, Fu J, Soranzo N, Gwilliam R, Deloukas P, Savelieva I, Zheng D, Dalageorgou C, Farrall M, Samani NJ, Connell J, Brown M, Dominiczak A, Lathrop M, Zeggini E, Wain LV, The Wellcome Trust Case Control Consortium, DCCT/EDIC Research Group, Newton-Cheh C, Eijgelsheim M, Rice K, de Bakker PI, QTGEN consortium, Pfeufer A, Sanna S, Arking DE, QTSCD consortium, Asselbergs, FW, Spector TD, Carter ND, Jeffery S, Tobin M, Caulfield M, Snieder H, Paterson AD, Munroe PB, Jamshidi Y. Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies. PLoS One 2009, 4(7):e6138. PMCID:2704957.
  • Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B, Sun L, Bull SB, and the DCCT/EDIC Research Group. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-Selectin. Atheroscler Thromb Vasc Biol 2009, 29(11):1958-1967. PMCID:3147250.
  • Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, DCCT/EDIC Research Group, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008, 49(4):847-855. PMID:18202432.
  • Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW, and the DCCT/EDIC Research Group. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008, 93(5):1893-1900. PMCID:2386274.
  • Virella G, Carter RE, Saad A, Crosswell EG, Game BA, DCCT/EDIC Research Group, Lopes-Virella MF. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 2008, 127(3):394-400. PMCID:2601558.
  • Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ, and the DCCT/EDIC Research Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 2008, 22(3), 153-163. PMID:18413218.
  • White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus. Arch Ophthalmol 2008, 126(12):1707-1715. PMCID:2663518.
  • Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G, and the DCCT/EDIC Study Group.  Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC Cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008, 31(10):2006-2012. PMCID:2551645.
  • Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, Ho M, McKnight AJ, Maxwell AP, Savage DA, Kidd KK, Kidd JR, Speed WC, Orchard TJ, Miller RG, Sun L, Bull SB, Paterson AD, and the DCCT/EDIC Study Group. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy. Diabetes 2008, 57(1):218-228. PMCID:2655325.
  • Musen G, Jacobson A, Ryan C, Cleary P, Waberski B, Weinger K, Dahms W, Bayless M, Silver N, Harth J, White N, and the DCCT/EDIC Research Group. The impact of diabetes and its treatments on cognitive function among adolescents who participated in the DCCT. Diabetes Care 2008, 31(10):1933-1938. PMCID:2551630.
  • de Boer IH, Kestenbaum B, Rue T, Steffes M, Cleary P, Molitch M, Lachin J, Weiss N, Brunzell J, and the DCCT/EDIC Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 2008, 168(17):1867-1873. PMCID:2701288.
  • Lachin J, Genuth S, Nathan D, Zinman B, Rutledge B, and the DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial – Revisited. Diabetes 2008, 57(4):995-1001. PMID:18223010.
  • Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). Diabetes Care 2008; 31(12):2338-2343. PMCID:2584192.
  • Nathan DM, Genuth S, Rutledge B and Lachin JM. Response to Comment on: Lachin et al. (2007) The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial: Diabetes 56(7):1913–1921, 2007. Diabetes 2008, 57(2):e5.
  • de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, Steffes MW, Weiss NS, Brunzell JD, and the DCCT/EDIC Research Group. Central obesity, incident microalbuminuria, and change in creatinine clearance in the Epidemiology of Diabetes Interventions and Complications study. J Am Soc Nephrol 2007, 18(1):235-243.  PMCID:2622719.
  • Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, Orchard TJ, and the DCCT/EDIC Research Group. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the Diabetes Control and Complications Trial. Diabetes Care 2007, 30(10):2646-2648. PMCID:2655324.
  • Albers J, Herman W, Pop-Busui R, Martin C, Cleary P, Waberski B, and the DCCT/EDIC Research Group. Subclinical neuropathy among diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion. Diabetes Care 2007, 30(10):2613-2618. PMCID: 2657957.
  • Sibley S, de Boer I, Steffes M, Brunzell J, and the DCCT/EDIC Research Group. Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes. Diabetes Care 2007, 30(7):1898-1900. PMCID:2699615.
  • AL-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull S, Boright AP, Paterson AD, and the DCCT/EDIC Research Group.  Multiple variants in Vascular Endothelial Growth Factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes. Diabetes 2007, 56(8):2161-2168.  PMID:17513698.
  • Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS, and the DCCT/EDIC Research Group. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.  Diabetes Care 2007, 30(8):2107-2112. PMCID:2654598.
  • Lachin JM, Genuth S, Nathan DM, and Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial.  Diabetes 2007, 56(7):1913-1921.  PMID:17360979.
  • The DCCT/EDIC Research Group (Writing Committee: Jacobson AM, Ryan CM, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Silvers N, Harth J, Munsen G). Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007, 356(18):1842-1852. PMCID:2701294.
  • Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G, and the DCCT/EDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007, 190(2):359-369. PMID:16530770.
  • Murdoch SJ, Boright AP, Paterson AD, Zinman B, Steffes M, Cleary P, Edwards K, Marcovina SS, Purnell JQ, Brunzell JD, and the DCCT/EDIC Research Group. LDL composition in E2/2 subjects and LDL distribution by APOE Genotype in type 1 diabetes. Atherosclerosis 2007, 192(1):138-147. PMCID:2628303.
  • Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort: Role of central obesity. Am J Kidney Dis 2006, 47(2):223-232. PMID:16431251.
  • Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee, D, Aston CE, Orchard TJ, Silvers N, Peng Y.G, McKnight JA, Baynes JW, Lyons TJ, and the DCCT/EDIC Research Group.  Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.  Diabetologia 2006, 49(10):2488-2498.  PMID:16955213.
  • Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL, and the DCCT/EDIC Research Group. Neuropathy among the Diabetes Control and Complication Trial cohort 8 years after trial completion.  Diabetes Care 2006, 29(2).2:340-344. PMCID:2622720.
  • Cleary  PA,  Orchard  TA,  Genuth  S,  Wong  ND,  Detrano  R,  Backlund  JC,  Zinman  B, Jacobson A, Sun W, Lachin JM, Nathan DM, and the DCCT/EDIC Research Group. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions  and  Complications  (DCCT/EDIC)  study.  Diabetes 2006, 55(12):3556-3565. PMCID:2701297.
  • Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella M, Garvey WT, and the DCCT/EDIC Research Group. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Associations with carotid intima-media thickness. Diabet Med 2006, 23(9):955-966. PMID:16922701.
  • Boright A, Paterson A, Mirea S, Bull S, Scherer B, Zinman B, and the DCCT/EDIC Research Group. Genetic variation at the ACE Gene is associated with persistent micoalbuminuria and severe nephropathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes 2005, 54(4):1238-1244. PMCID:1621110.
  • Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, and the DCCT/EDIC Research Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes.  Diabetes 2005, 54(11):3103-3111. PMCID:2622724.
  • The DCCT/EDIC Research Group (Writing Committee: Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353(25):2643-2653. PMC2637991.
  • Steffes M, Cleary P, Goldstein R, Little R, Wiedmeyer H M, Rohlfing C, England J, Bucksa J, Norwicki M, and the DCCT/EDIC Research Group. Hemoglobin (HbA1c) measurements over nearly two decades:  Sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study.  Clin Chem 2005, 51(4):753-758. PMCID:2635091.
  • Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM. Effect of intensive glycemic control on levels of markers of inflammation in Type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005, 111(19):2446-2453. PMID:15867184.
  • Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, and the DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications 2005, 19(1):18-25. PMID:15642486.
  • Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Brown WV, Lyons TJ, Garvey WT, and the DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism 2004, 53(10):1296-1304. PMID:15375785.
  • Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL, and the DCCT/EDIC Research Group. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004, 45(3):910-918. PMID: 14985310.
  • Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004; 53(11): 2883-2892. PMID:15504969
  • Purnell JQ, Dev RK, Steffes MW, Cleary PA, Palmer JP, Hirsch IB, Hokanson JE, Brunzell JD.  Relationship of family history of type 2 diabetes, hypoglycemia and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.  Diabetes 2003, 52(10):2623-2629. PMCID:2632607.
  • Purnell JQ, Tsai A, Hokanson J, Cleary PA, Steffes M, Jacobs D, Brunzell J. Weight gain with intensive therapy but not conventional therapy of type 1 diabetes in DCCT is greater than a non-diabetic population (CARDIA): Follow-up from 1985–1993. Diabetes 2003, 50(Suppl 2) A208.
  • Sibley S, Palmer J, Hirsch I, Brunzell JD. Visceral obesity, hepatic lipase activity and dyslipidemia in type I diabetes. J Clin Endocrinol Metab 2003, 88(7):3379-3384. PMID:12843191.
  • Cheung MC, Sibley SD, Palmer JP, Oram JF, Brunzell JD. Lipoprotein lipase and hepatic lipase: Their relationship with HDL subspecies Lp(A-I) and Lp(A-I, A-II). J Lipid Res 2003, 44(8):1552-1558. PMCID:2768368.
  • The DCCT/EDIC Research Group (Writing Committee: Steffes M, Molitch M, Chavers B, Cleary P, Lachin J, Genuth S, Nathan D). Sustained effect of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy in Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290(16):2159-2167. PMC2622725.
  • The DCCT/EDIC Research Group (Writing Committee: Nathan DM, Lachin JM, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth SM). Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348(23):2294-2303. PMC2701300.
  • Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH, and the DCCT/EDIC Study Group. Plasma prekallikrein: A risk marker for hypertension and nephropathy in type-1 diabetes.  Diabetes 2003, 52(5):1215-1221. PMID:12716755.
  • Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT, and the DCCT/EDIC Study Group.  Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort.  Diabetes Care 2003, 26(5):1439-1448.  PMID:12716802.
  • Jenkins AJ, Garvey WT, and Klein RL, and the DCCT/EDIC Research Group. Lipoprotein abnormalities in type 1 diabetes. Curr Opin Endocrinol Diabetes 2003, 10(4):245-250.
  • Jenkins AJ, Lyons TJ, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, and the DCCT/EDIC Research Group.  Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort: Associations with gender and glycemia. Diabetes Care 2003, 26(3):810-818. PMID:12610042.
  • Jenkins AJ, Lyons TJ, Zheng D, Otvos J, Lackland DT, McGee D, Garvey WT, Klein R, and the DCCT/EDIC Research Group.  Lipoprotein in the DCCT/EDIC cohort: Associations with diabetic nephropathy.  Kidney Int 2003, 64(3):817-828. PMID:12911531.
  • Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF, and the DCCT/EDIC Research Group.  Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003, 44(3):487-93. PMID:12562876.
  • The DCCT/EDIC Research Group (Writing Committee: Lipps J, Lorenzi G, Genuth S, Nathan D, Davis M, Lachin J, Cleary P). The effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.  JAMA 2002, 287(19):2563-2569.  PMC2622728.
  • Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G. Oxidized LDL-Anti-Oxidized LDL immune complexes and diabetic nephropathy.  Diabetologia 2002, 45(11):1562-1571.  PMID:12436340.
  • Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, and the DCCT/EDIC Research Group.  Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002, 105(1):81-92. PMID:12483997.
  • White N, Cleary P, Dahms W, Goldstein D, Malone J, Tamborlane W, and the DCCT/EDIC Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001, 139(6):804-812. PMID:11743505.
  • The DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial.  Diabetes Care 2001, 24(10):1711-1721. PMCID:2663516.
  • The DCCT/EDIC Research Group (Writing Committee: Lachin J, Genuth S, Nathan D, Davis M, Cleary P). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.  N Engl J Med 2000, 342(6):381-389. PMCID: 2630213.
  • The DCCT Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 2000, 23 (8):1084-1091. PMCID:2631985.

STATISTICAL METHODS

  • Lachin JM. Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. Stat Med 2008, 27(14):2509-2523. PMCID:3626499.
  • Sparling YH, Younes N, Lachin JM, Bautista OM.  Parametric survival models for interval-censored data with time-dependent covariates.  Biostatistics, 2006, 7(4):599-614. PMID:16597670.
  • Lachin JM, Cleary PA, Crofford C, Genuth S, Nathan D, Clark C, Ferris F, Siebert C for the DCCT Research Group. Early termination of the diabetes control and complications trial. In Data Monitoring in Clinical Trials: A Case Studies Approach, DL DeMets, CD Furberg, LM Friedman (Eds). Springer, New York, New York, 2006, pp. 93-108.
  • Lachin JM. Maximum information designs.  Clin Trials 2005, 2(5):453-464. PMID:16315649.
  • Lachin JM, Greenhouse SW, Bautista OM. Group sequential large sample T2 –like X2 tests for multivariate observations.  Stat Med 2003, 22(21):3357-3368. PMID:14566920.
  • Lan KKG, Lachin JM, Bautista OM.  Over-ruling a group sequential boundary – a stopping rule versus a guideline.  Stat Med 2003, 22(21):3347-3355. PMID:14566919.